Skip to main content

Table 2 Patient characteristics at survey evaluation by cohort, Arua, Uganda, 2006

From: Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda

Children aged < 15 years M12 cohort
(N = 59)
M24 cohort
(N = 27)
Type of caregiver (%)   
   Mother 30 (50.8) 10 (37.0)
   Father 6 (10.2) 3 (11.1)
   Another relative 21 (35.6) 13 (48.2)
   Other 2 (3.4) 1 (3.7)
Father receiving ART (%) 17 (28.8) 4 (14.8)
Mother receiving ART (%) 29 (49.2) 11 (40.7)
Both parents died (%) 12 (20.3) 6 (22.2)
Clinico-immunological characteristics   
Cumulative clinical stage (%)   
   Stage 1/2 13 (22.0) 3 (11.1)
   Stage 3 26 (44.1) 10 (37.0)
   Stage 4 20 (33.9) 14 (51.9)
Weight gain, kg, median [IQR] 4 [3-5] 5 [4-7]
Weight-for-height z-score (%) n = 51 n = 22
   < -2 z-score 2 (3.9) 2 (9.1)
Reported ARV-related toxicity   
   Asthenia 8 (13.6) 2 (7.4)
   Gastrointestinal symptoms 25 (42.4) 12 (44.4)
   Neurological disorders 23 (39.7) 10 (37.0)
   Morphological disorders 13 (22.0) 5 (18.5)
Adherence to ART   
4-day recall (%)   
   Good (100%) 49 (83) 23 (85)
   Moderate (95-99%) 10 (17) 4 (15)
   Poor (< 95%) 0 (0) 0 (0)
30-day VASa (%)   
   Good (100%) 28 (48) 19 (70)
   Moderate (95-99%) 22 (38) 5 (19)
   Poor (< 95%) 8 (14) 3 (11)
Median CD4 testing [IQR]   
   CD4 cell count, cell/μL n = 33 n = 16
  504 [399-715] 210 [124-458]
   CD4% n = 26 n = 11
  25 [21-29] 20 [16-27]
Plasma EFV concentrations (%) n = 5  
   Low (< 1,000 ng/mL) 1 (20.0) -
   High (> 4,000 ng/mL) 1 (20.0)  
Plasma NVP concentrations (%) n = 54 n = 27
   Low (< 4,000 ng/mL) 18 (33.3) 6 (22.2)
   High (> 8,000 ng/mL) 9 (16.7) 2 (7.4)
  1. Note: ARV, antiretroviral; ART, antiretroviral therapy; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; VAS, visual analogue scale.
  2. aMissing information for one patient in the M12 cohort.